

Daniel Sussman, MD, Esq., MBA

1785 E. Sahara Avenue
Las Vegas, Nevada 89104
Office: (702) 486-6627

Pharmacy and Therapeutics Committee
State of Nevada Dept. of Health and Human Services
Division of Health Care Financing and Policy
1100 E. William Street, Suite 101
Carson City, Nevada 89701

Re: December 9, 2021 Agenda item 5.f.

I write to request that you add Caplyta (lumateperone) to the Nevada Medicaid Preferred Antipsychotic Drug List at your December 9, 2021 meeting.

I have no bias, as I have never been paid to research or speak for this medication. I have found it to be useful for several patients suffering from psychotic illnesses.

It has advantages over many of the other anti-psychotic medications on the preferred list such as (1) once daily dosing requiring no titration, (2) no significant difference from placebo for metabolic derangement, (3) EPS profile similar to placebo, and (4) It can be useful for comorbid insomnia.

In summary, its efficacy, and advantages noted just above make it beneficial to both patients and prescribers.

I appreciate your considering adding Caplyta to the Nevada Medicaid Preferred Formulary.

Respectfully Submitted,

A handwritten signature in blue ink, appearing to read 'D. Sussman', is written over the typed name.

Daniel Sussman, MD, Esq., MBA
Diplomate of the American Board of Psychiatry & Neurology
Nevada License # 10116